Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
Dengue
Human papillomavirus (HPV)
SAGE documentation
2017
Clear all
Type of publications
NITAG documentation
(16)
SAGE documentation
(11)
Systematic reviews (SYSVAC)
(20)
Topics
Evidence to recommendation table
(3)
GRADE table
(6)
Position paper
(2)
Regions
Countries
Diseases
Dengue
(1)
Human papillomavirus (HPV)
(10)
Cholera
(2)
Diphtheria
(3)
Hepatitis B
(3)
Measles
(10)
Pneumococcal disease
(3)
Poliomyelitis
(1)
Rabies
(3)
Tetanus
(1)
Typhoid
(4)
Yellow fever
(1)
Publication date
2017
(11)
2022
(2)
2018
(9)
2015
(2)
2014
(2)
2008
(1)
Target population
Available to download in languages
English (EN)
(10)
French (FR)
(1)
11 results found
2017
∙
SAGE
Efficacy of 2 vs. 3 doses of HPV vaccination in immunocompetent girls
2017
∙
SAGE
Efficacy of HPV vaccination in HIV infected girls
2017
∙
SAGE
Efficacy of' HPV vaccination in adolescent girls
2017
∙
SAGE
Human papillomavirus vaccines: WHO position paper
2017
∙
SAGE
Immunogenicity of 2 vs. 3 doses of HPV vaccination in immunocompetent girls
2017
∙
SAGE
In 9 to 15-year old females, is 9-valent human papillomavirus vaccine (HPV) vaccine superior to 4-valent or 2-valent HPV vaccines?
2017
∙
SAGE
Protection of anogenital warts conferred by HPV vaccination in immunocompetent girls
2017
∙
SAGE
Safety of HPV vaccination in HIV infected girls
2017
∙
SAGE
What is the incremental effectiveness and cost-effectiveness of vaccinating multiple age cohorts versus a single age cohort in high income countries (HIC) and low and middle income countries (LMIC)?
2017
∙
SAGE
What is the public health impact on cervical cancer of administering HPV vaccine to 9 to 15-year old females and males versus to 9 to 15-year old females?
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register